XML 112 R93.htm IDEA: XBRL DOCUMENT
v3.20.2

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 28, 2020 | Jun. 30, 2019 | Jun. 28, 2020 | Jun. 30, 2019
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [1] | $ 11,801 | $ 13,264 | $ 23,829 | $ 26,382
Biopharma, Upjohn And Consumer Healthcare Segments [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 11,801 | 13,264 | 23,829 | 26,382
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,404 | 1,187 | 2,786 | 2,277
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 289 | 217 | 578 | 396
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [3] | 1,237 | 1,218 | 2,644 | 2,455
Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 9,795 | 9,432 | 19,802 | 18,477
Internal Medicine [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 2,279 | 2,243 | 4,610 | 4,380
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 1,272 | 1,085 | 2,572 | 2,096
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 235 | 276 | 505 | 549
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 152 | 193 | 304 | 361
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 57 | 79 | 127 | 145
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 64 | 65 | 124 | 125
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 498 | 544 | 978 | 1,103
Oncology [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 2,647 | 2,236 | 5,082 | 4,198
Oncology [Member] | Biopharma [Member] | Ibrance [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,349 | 1,261 | 2,598 | 2,394
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 266 | 201 | 475 | 369
Oncology [Member] | Biopharma [Member] | Sutent [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 209 | 248 | 414 | 480
Oncology [Member] | Biopharma [Member] | Inlyta [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 195 | 104 | 364 | 177
Oncology [Member] | Biopharma [Member] | Xalkori [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 138 | 133 | 287 | 255
Oncology [Member] | Biopharma [Member] | Bosulif [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 113 | 97 | 213 | 177
Oncology [Member] | Biopharma [Member] | Retacrit [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 87 | 51 | 176 | 82
Oncology [Member] | Biopharma [Member] | Braftovi [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 36 | 0 | 74 | 0
Oncology [Member] | Biopharma [Member] | Mektovi [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 32 | 0 | 69 | 0
Oncology [Member] | Biopharma [Member] | All other Oncology [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 221 | 140 | 412 | 262
Hospital [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 1,794 | 1,838 | 3,807 | 3,665
Hospital [Member] | Biopharma [Member] | Sulperazon [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 102 | 165 | 289 | 342
Hospital [Member] | Biopharma [Member] | Medrol [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 78 | 120 | 207 | 240
Hospital [Member] | Biopharma [Member] | Zithromax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 55 | 73 | 193 | 177
Hospital [Member] | Biopharma [Member] | Precedex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 114 | 40 | 156 | 80
Hospital [Member] | Biopharma [Member] | Vfend [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 75 | 94 | 149 | 178
Hospital [Member] | Biopharma [Member] | Panzyga [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 63 | 44 | 136 | 61
Hospital [Member] | Biopharma [Member] | Zyvox [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 55 | 71 | 125 | 134
Hospital [Member] | Biopharma [Member] | Fragmin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 58 | 63 | 118 | 123
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5],[6] | 224 | 204 | 376 | 380
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 367 | 420 | 811 | 825
Hospital [Member] | Biopharma [Member] | All other Hospital [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4],[5] | 603 | 544 | 1,245 | 1,124
Vaccines [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,247 | 1,375 | 2,857 | 2,988
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,116 | 1,179 | 2,566 | 2,665
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 56 | 58 | 130 | 107
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 75 | 138 | 161 | 215
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 1,149 | 1,219 | 2,127 | 2,256
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 635 | 613 | 1,086 | 1,036
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 337 | 420 | 684 | 871
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [2] | 150 | 153 | 308 | 291
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 26 | 34 | 48 | 59
Rare Disease [Member] | Biopharma [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 681 | 521 | 1,319 | 991
Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 277 | 63 | 508 | 104
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 109 | 121 | 230 | 247
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 106 | 125 | 209 | 232
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 91 | 108 | 181 | 214
Rare Disease [Member] | Biopharma [Member] | Somavert [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 67 | 68 | 131 | 128
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues |  | 31 | 35 | 61 | 66
Upjohn [Member] | Upjohn [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 2,006 | 2,970 | 4,027 | 6,184
Upjohn [Member] | Upjohn [Member] | Lipitor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 431 | 407 | 836 | 1,029
Upjohn [Member] | Upjohn [Member] | Lyrica [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 349 | 1,175 | 706 | 2,362
Upjohn [Member] | Upjohn [Member] | Norvasc [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 222 | 216 | 419 | 516
Upjohn [Member] | Upjohn [Member] | Celebrex [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 139 | 174 | 295 | 347
Upjohn [Member] | Upjohn [Member] | Viagra [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 94 | 114 | 222 | 259
Upjohn [Member] | Upjohn [Member] | Effexor [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 86 | 86 | 163 | 163
Upjohn [Member] | Upjohn [Member] | Zoloft [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 79 | 73 | 157 | 143
Upjohn [Member] | Upjohn [Member] | EpiPen [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 64 | 67 | 136 | 123
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 65 | 72 | 126 | 133
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [4] | 476 | 587 | 968 | 1,109
Consumer Healthcare [Member] | Consumer Healthcare [Member] |  |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |  |
Revenues | [7] | $ 0 | $ 862 | $ 0 | $ 1,721
[1] | Amounts may not add due to rounding.
[2] | Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
[3] | Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
[4] | Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
[5] | Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
[6] | Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
[7] | On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ChantixChampixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PremarinFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BMP2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_IbranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SutentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InlytaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalkoriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_RetacritMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BraftoviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MektoviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_HospitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SulperazonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_MedrolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrecedexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VfendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PanzygaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZyvoxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_FragminMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_VaccinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_NimenrixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_VyndaqelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_BeneFIXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_GenotropinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_SomavertMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LipitorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_LyricaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_NorvascMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_CelebrexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ViagraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EffexorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_ZoloftMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_EpiPenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_XalatanXalacomMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pfe_AllOtherUpjohnProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |